Table 1. EtOH Intake (g/kg) affected by CRF-R1 and CRF-R2 antagonists.

Ethanol consumption (g/kg) over time after intra-VTA microinjection of CRF-R1 antagonist CP376395 or CRF-R2 antagonist Astressin2B after 4 weeks of continuous EtOH, intermittent EtOH, or intermittent EtOH and social defeat stress.

Group	Drug	Dose	2 hr	4 hr	24 hr
Continuous EtOH	CP376395	ACSF	2.90 ± 0.39	5.60 ± 0.50	16.47 ± 1.22
		0.3 µg	2.75 ± 0.57	5.32 ± 0.61	17.67 ± 1.46
		0.6 µg	2.46 ± 0.48	4.53 ± 0.55	15.41 ± 1.20
	Astressin2B	ACSF	3.38 ± 0.39	5.86 ± 0.35	16.04 ± 1.38
		0.5 µg	2.60 ± 0.59	5.53 ± 0.96	15.53 ± 1.70
Intermittent EtOH	CP376395	ACSF	3.73 ± 0.44	6.36 ± 0.42	22.28 ± 2.16
		0.3 µg	2.85 ± 0.55*	5.52 ± 0.64	20.34 ± 2.59
		0.6 µg	2.19 ± 0.48**	4.80 ± 0.55*	18.89 ± 1.72*
	Astressin2B	ACSF	2.69 ± 0.40	5.60 ± 0.38	22.10 ± 1.29
		0.25 µg	2.36 ± 0.19	5.33 ± 0.38	19.01 ± 1.42
		0.5 µg	2.19 ± 0.25	4.51 ± 0.41	19.72 ± 2.14
Stress + Intermittent EtOH	CP376395	ACSF	4.42 ± 0.29	7.35 ± 0.35	26.54 ± 1.48
		0.3 µg	3.13 ± 0.22*	6.30 ± 0.32*	25.28 ± 1.61
		0.6 µg	2.41 ± 0.34**	5.33 ± 0.33**	20.58 ± 1.40*
	Astressin2B	ACSF	3.92 ± 0.38	6.80 ± 0.52	29.11 ± 2.20
		0.25 µg	3.05 ± 0.41	5.43 ± 0.71	26.79 ± 1.18
		0.5 µg	2.27 ± 0.35*	6.24 ± 0.49	26.15 ± 2.57

^*p<0.05 vs. ACSF,

^**p<0.001 vs. ACSF.